Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations.
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
- Details
- Category: AstraZeneca
AstraZeneca and Amgen have announced that AMAGINE-2™, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12.
GSK statement on first phase 1 trial results of a candidate Ebola vaccine
- Details
- Category: GlaxoSmithKline
First results from a small phase 1 trial published yesterday in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it.
Bristol-Myers Squibb and Five Prime Therapeutics announce exclusive clinical collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
Novartis Foundation symposium showcases sustainable healthcare interventions
- Details
- Category: Novartis
Today, the Novartis Foundation, formerly named the Novartis Foundation for Sustainable Development, convenes its annual symposium. This year's topic - "Sustainable healthcare interventions: from blueprint to lasting impact" - brings together philanthropists, local partners and innovators to explore the journey from idea generation and pilot projects to the realization of scalable and sustainable healthcare systems that improve outcomes for patients in low- and middle-income countries.
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
- Details
- Category: Boehringer Ingelheim
Two new real-world data analyses presented at the American Heart Association's Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin.(1,2)
Novo Nordisk second best in the world at providing access to medicine
- Details
- Category: Novo Nordisk
Today, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities.
More Pharma News ...
- Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Ireland
- AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
- Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China
- Bayer operationally strong - strategic focus on Life Science businesses
- AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
- Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
- AstraZeneca strengthens partnership with the University of Cambridge